摘要
目的探讨康柏西普眼用注射液治疗渗出型年龄相关性黄斑变性的有效性及安全性。方法 60例渗出型年龄相关性黄斑变性患者,按照治疗方法不同分为观察组和对照组,各30例。观察组给予康柏西普眼用注射液治疗,对照组给予光动力治疗,比较两组治疗前后眼内压(IOP)、视力、黄斑中心凹视网膜厚度(CMT)、荧光素渗漏率、脉络膜新生血管(CNV)面积,并观察不良反应发生情况。结果治疗前,两组IOP、视力比较差异无统计学意义(P>0.05);治疗后,观察组IOP(12.21±2.04)mm Hg(1 mm Hg=0.133 k Pa)、视力(0.321±0.047)log MAR与对照组的(14.18±1.98)mm Hg、(0.438±0.062)log MAR比较,差异具有统计学意义(P<0.05)。治疗前,两组CMT、荧光素渗漏率、CNV面积比较差异无统计学意义(P>0.05);治疗后,两组CMT、荧光素渗漏率、CNV面积比较,差异具有统计学意义(P<0.05)。两组均未出现严重不良反应,观察组有1例暂时性眼压升高,3例注射部位球结膜下出血,症状较轻,自行恢复。结论康柏西普眼用注射液相比较传统的光动力治疗,对于渗出型年龄相关性黄斑变性的临床治疗效果更好,且不良反应少,症状轻,安全性好,值得推广。
Objective To investigate the effectiveness and safety of conbercept ophthalmic injection in the treatment of exudative age-related macular degeneration. Methods A total of 60 patients with exudative agerelated macular degeneration were divided by different treatment methods into observation group and control group, with 30 cases in each group. The observation group was treated with conbercept ophthalmic injection, and the control group was treated with photodynamics therapy. Intraocular pressure（IOP）, visual acuity, central macular thickness（CMT）, fluorescein leakage rate, choroidal neovascularization（CNV） area before and after treatment were compared between the two groups, and the occurrence of adverse reactions was observed. Results Before treatment, both groups had no statistically significant difference in IOP and visual acuity（P〉0.05）.After treatment, the observation group had statistically significant difference in IOP as（12.21±2.04） mm Hg（1 mm Hg=0.133 k Pa）, visual acuity as（0.321±0.047） log MAR, comparing with（14.18±1.98） mm Hg and（0.438±0.062） log MAR in the control group（P〈0.05）. Before treatment, both groups had no statistically significant difference in CMT, fluorescein leakage rate and CNV area（P〈0.05）. After treatment, both groups had statistically significant difference in CMT, fluorescein leakage rate and CNV area（P〈0.05）. There were no serious adverse reactions in the two groups. The observation group had 1 case of elevated transient intraocular pressure, 3 cases of subconjunctival hemorrhage at the injection site. The symptoms were mild, and they recovered spontaneously. Conclusion Compared with the traditional photodynamic therapy, conbercept ophthalmic injection shows better effect in clinical treatment for exudative age-related macular degeneration, with less adverse reactions, mild symptoms and high safety. It is worth popularizing.
作者
廖明怡
LIAO Ming-yi(Shenzhen Ophthalmology Hospital,Shenzhen 518040,China)
出处
《中国现代药物应用》
2018年第12期84-86,共3页
Chinese Journal of Modern Drug Application
关键词
康柏西普
渗出型年龄相关性黄斑变性
有效性
安全性
Conbercept ophthalmic
Exudative age-related macular degeneration
Effectiveness
Safety
